Changes of Serum Homocysteine and Vitamin B12, but Not Folate Are Correlated With Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis of Case-Control Studies

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2022 May 26

PMID 35615448

Authors

Sirui Yan

Hailong Liu

Yaqiong Yu

Nashu Han

Wenzhi Du

Affiliations

Soon will be listed here.

Abstract

Background: Obsessive-compulsive disorder (OCD) a complex neuropsychiatric disorder, is characterized by irresistible obsessive thinking and compulsive behavior. Folate is a member of water-soluble vitamins in the human body and sustains many normal daily activities (e.g., exercise, sleep, and memory). Homocysteine, a sulfur-containing non-essential amino acid, has been investigated in numerous psychiatric disorders (e.g., OCD). Vitamin B12 is a type of complex organic compound with cobalt contained. Moreover, vitamin B12 and folate deficiency and high levels of homocysteine were found to have an effect on brain functions and also lead to non-specific psychiatric symptoms.

Objectives: This study aimed to confirm the epidemiological evidence of OCD and investigate whether vitamin B12, folate, and homocysteine have an effect on the etiology of OCD.

Methods: A systematic search was conducted on eight databases (i.e., PubMed, Embase, Web of Science, the Cochrane Library, China Biology Medicine disc, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database), and the retrieval time was up to March 2021. The available articles involving patients with OCD with/without abnormal serum levels of vitamin B12, folate, and homocysteine were comprehensively reviewed and analyzed.

Results: A total of 5 studies involving 309 patients were included in this meta-analysis, including 172 cases in the experimental group and 137 in the control group. The content of folate in the OCD group was not significantly different from that in the control group (SMD = -0.089, 95%CI -0.755 to 0.577, = 0.794). And serum homocysteine was significantly higher in the patients with OCD (SMD = 1.132, 95%CI 0.486 to 1.778, = 0.001). Vitamin B12 was significantly lower in patients with OCD (SMD = -0.583, 95%CI -0.938 to -0.229, = 0.001).

Conclusions: This meta-analysis shows serum high levels of homocysteine, low levels of vitamin B12, and normal folate level are closely correlated with OCD. However, high-quality case-control studies should be further conducted to explore the correlation between serum levels of vitamin B12, folate, homocysteine, and OCD.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021262161; PROSPERO (Number CRD#42021262161).

Citing Articles

Unraveling Gender Differences in Obsessive-Compulsive Disorder: A Focus on Key Micronutrients.

Algin S, Sajib M, Ahmed S, Siddique M, Reza M, Tanzilla N Cureus. 2025; 17(2):e79667.

PMID: 40017580 PMC: 11865865. DOI: 10.7759/cureus.79667.

Relationship between serum homocysteine, folate and vitamin B12 levels and cognitive function in patients with drug-naive obsessive-compulsive disorder.

Ding Y, Lu S, Wang S, Wang Y, Wu C, Du Y Sci Rep. 2025; 15(1):6703.

PMID: 40000847 PMC: 11862116. DOI: 10.1038/s41598-025-91618-4.

Machine learning in obsessive-compulsive disorder medications.

Khazaneha M, Bakhshinejad B, Mehrabani M, Sabahi A, Khaksari M, Shafiee M Heliyon. 2024; 10(21):e40136.

PMID: 39583807 PMC: 11582411. DOI: 10.1016/j.heliyon.2024.e40136.

Silent Infections are not So Silent: The Emerging Role of Combined Infections, Inflammation, and Vitamin Levels in OCD.

Marazziti D, Massa L, Carbone M, Palermo S, Arone A, DAngelo G Clin Neuropsychiatry. 2024; 21(1):7-21.

PMID: 38559435 PMC: 10979795. DOI: 10.36131/cnfioritieditore20240101.

References

Lucock M . Is folic acid the ultimate functional food component for disease prevention?. BMJ. 2004; 328(7433):211-4. PMC: 318492. DOI: 10.1136/bmj.328.7433.211. View

Bottiglieri T . Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev. 1996; 54(12):382-90. DOI: 10.1111/j.1753-4887.1996.tb03851.x. View

Esnafoglu E, Yaman E . Vitamin B12, folic acid, homocysteine and vitamin D levels in children and adolescents with obsessive compulsive disorder. Psychiatry Res. 2017; 254:232-237. DOI: 10.1016/j.psychres.2017.04.032. View

Castillo-Lancellotti C, Margozzini P, Valdivia G, Padilla O, Uauy R, Rozowski J . Serum folate, vitamin B12 and cognitive impairment in Chilean older adults. Public Health Nutr. 2015; 18(14):2600-8. PMC: 10271379. DOI: 10.1017/S1368980014003206. View

Arnold P, Rosenberg D, Mundo E, Tharmalingam S, Kennedy J, Richter M . Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004; 174(4):530-8. DOI: 10.1007/s00213-004-1847-1. View

Zintzaras E . C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatr Genet. 2006; 16(3):105-15. DOI: 10.1097/01.ypg.0000199444.77291.e2. View

Lazarou C, Kapsou M . The role of folic acid in prevention and treatment of depression: an overview of existing evidence and implications for practice. Complement Ther Clin Pract. 2010; 16(3):161-166. DOI: 10.1016/j.ctcp.2010.01.003. View

Taylor S . Etiology of obsessions and compulsions: a meta-analysis and narrative review of twin studies. Clin Psychol Rev. 2011; 31(8):1361-72. DOI: 10.1016/j.cpr.2011.09.008. View

Robins Wahlin T, Wahlin A, Winblad B, Backman L . The influence of serum vitamin B12 and folate status on cognitive functioning in very old age. Biol Psychol. 2001; 56(3):247-65. DOI: 10.1016/s0301-0511(01)00079-5. View

10.

Hermesh H, Weizman A, Shahar A, Munitz H . Vitamin B12 and folic acid serum levels in obsessive compulsive disorder. Acta Psychiatr Scand. 1988; 78(1):8-10. DOI: 10.1111/j.1600-0447.1988.tb06294.x. View

11.

Aoyama K, Suh S, Hamby A, Liu J, Chan W, Chen Y . Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci. 2005; 9(1):119-26. DOI: 10.1038/nn1609. View

12.

Muntjewerff J, Kahn R, Blom H, den Heijer M . Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2005; 11(2):143-9. DOI: 10.1038/sj.mp.4001746. View

13.

Klanker M, Feenstra M, Denys D . Dopaminergic control of cognitive flexibility in humans and animals. Front Neurosci. 2013; 7:201. PMC: 3817373. DOI: 10.3389/fnins.2013.00201. View

14.

Welch J, Lu J, Rodriguiz R, Trotta N, Peca J, Ding J . Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007; 448(7156):894-900. PMC: 2442572. DOI: 10.1038/nature06104. View

15.

Purcell R, Maruff P, Kyrios M, Pantelis C . Neuropsychological deficits in obsessive-compulsive disorder: a comparison with unipolar depression, panic disorder, and normal controls. Arch Gen Psychiatry. 1998; 55(5):415-23. DOI: 10.1001/archpsyc.55.5.415. View

16.

Regland B, Johansson B, Grenfeldt B, Hjelmgren L, Medhus M . Homocysteinemia is a common feature of schizophrenia. J Neural Transm Gen Sect. 1995; 100(2):165-9. DOI: 10.1007/BF01271539. View

17.

Skapinakis P, Caldwell D, Hollingworth W, Bryden P, Fineberg N, Salkovskis P . Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016; 3(8):730-739. PMC: 4967667. DOI: 10.1016/S2215-0366(16)30069-4. View

18.

Johnson W . DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders. Am J Med Genet. 1999; 88(4):311-23. View

19.

Shugart Y, Samuels J, Willour V, Grados M, Greenberg B, Knowles J . Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. Mol Psychiatry. 2006; 11(8):763-70. DOI: 10.1038/sj.mp.4001847. View

20.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View